Elanco Animal Health Incorporated Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Elanco Animal Health Incorporated (ELAN) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $4.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- Elanco Animal Health Incorporated effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$5.00M, a 117.24% decline year-over-year.
- Elanco Animal Health Incorporated effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $29.00M.
- Elanco Animal Health Incorporated effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$19.00M.
- Elanco Animal Health Incorporated effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$1.00M.
- Elanco Animal Health Incorporated effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $71.00M.
- Elanco Animal Health Incorporated effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$91.00M.
- Elanco Animal Health Incorporated effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$12.00M.
- Elanco Animal Health Incorporated effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$17.00M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.00M 10-Q · filed 2026-08-05 | |||||||
| 2026-03-31 | -$5.00M 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | $71.00M 10-K · filed 2026-02-24 | |||||||
| 2025-09-30 | $57.00M 10-Q · filed 2025-11-05 | |||||||
| 2025-06-30 | $56.00M 10-Q · filed 2026-08-05 | |||||||
| 2025-03-31 | $29.00M 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | -$91.00M 10-K · filed 2026-02-24 | |||||||
| 2024-09-30 | -$14.00M 10-Q · filed 2025-11-05 | |||||||
| 2024-06-30 | -$22.00M 10-Q · filed 2025-08-07 | |||||||
| 2024-03-31 | -$19.00M 10-Q · filed 2025-05-07 | |||||||
| 2023-12-31 | -$12.00M 10-K · filed 2026-02-24 | |||||||
| 2023-09-30 | -$12.00M 10-Q · filed 2024-11-07 | |||||||
| 2023-06-30 | -$9.00M 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | -$1.00M 10-Q · filed 2024-05-08 | |||||||
| 2022-12-31 | -$17.00M 10-K · filed 2025-02-25 | |||||||
| 2022-09-30 | -$49.00M 10-Q · filed 2023-11-07 | |||||||
| 2022-06-30 | -$19.00M 10-Q · filed 2023-08-07 | |||||||
| 2022-03-31 | -$5.00M 10-Q · filed 2023-05-09 | |||||||
| 2021-12-31 | -$31.00M 10-K · filed 2024-02-26 | |||||||
| 2021-09-30 | -$23.00M 10-Q · filed 2022-11-08 | |||||||
| 2021-06-30 | -$17.00M 10-Q · filed 2022-08-08 | |||||||
| 2021-03-31 | -$25.00M 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $27.00M 10-K · filed 2023-03-01 | $26.60M 10-K · filed 2021-03-01 | ||||||
| 2020-09-30 | $7.00M 10-Q · filed 2021-11-05 | $7.30M 10-Q · filed 2020-11-06 | ||||||
| 2020-06-30 | -$2.00M 10-Q · filed 2021-08-09 | -$1.80M 10-Q · filed 2020-07-30 | ||||||
| 2020-03-31 | -$9.00M 10-Q · filed 2021-05-07 | -$9.30M 10-Q · filed 2020-05-07 | ||||||
| 2019-12-31 | -$17.00M 10-K · filed 2022-02-28 | -$16.90M 10-K · filed 2020-02-28 | ||||||
| 2019-09-30 | $4.10M 10-Q · filed 2020-11-06 | |||||||
| 2019-06-30 | -$11.80M 10-Q · filed 2020-07-30 | |||||||
| 2019-03-31 | -$14.50M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $29.00M 10-K · filed 2021-03-01 | |||||||
| 2018-09-30 | $15.40M 10-Q · filed 2019-11-08 | |||||||
| 2018-06-30 | -$5.10M 10-Q · filed 2019-08-13 | |||||||
| 2018-03-31 | $3.90M 10-Q · filed 2019-05-14 | |||||||
| 2017-12-31 | $7.90M 10-K · filed 2020-02-28 | |||||||
| 2017-09-30 | $3.30M 10-Q · filed 2018-11-08 | |||||||
| 2016-12-31 | -$26.00M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |